Table. Baseline Demographics of Patients With Hepatocellular Carcinoma.
| Characteristic | Cohort, No. (%) | ||
|---|---|---|---|
| Total HCC | Discovery | Validation cohort | |
| No. | 132 | 50 | 82 |
| Age, median (IQR) | 61 (55-69) | 61 (55-70) | 61 (53-68) |
| Male sex | 111 (84.1) | 41 (82.0) | 70 (85.4) |
| ECOG performance status | |||
| 0 | 71 (53.8) | 25 (50.0) | 46 (56.1) |
| 1 | 61 (46.2) | 25 (50.0) | 36 (43.9) |
| Child-Pugh classification | |||
| A5 | 86 (65.2) | 35 (70.0) | 51 (62.2) |
| A6 | 46 (34.8) | 15 (30.0) | 31 (37.8) |
| Barcelona Clinical liver cancer stage | |||
| B | 24 (18.2) | 10 (20.0) | 14 (17.1) |
| C | 108 (81.8) | 40 (80.0) | 68 (82.9) |
| Alpha-fetoprotein ≥400 ng/mL | 42 (31.8) | 16 (32.0) | 26 (31.7) |
| Neutrophil to lymphocyte ratio, median (IQR) | 2.6 (1.7-4.2) | 2.7 (1.6-4.4) | 2.6 (1.8-4.0) |
| Presence of macrovascular invasion | 55 (41.7) | 20 (40.0) | 35 (42.7) |
| Presence of extrahepatic spread | 74 (56.1) | 28 (56.0) | 46 (56.1) |
| Etiology of HCC | |||
| Hepatitis B | 89 (67.4) | 34 (68.0) | 55 (67.1) |
| Hepatitis C | 7 (5.3) | 4 (8.0) | 3 (3.7) |
| Alcohol | 21 (15.9) | 8 (16.0) | 13 (15.9) |
| Other or unknown | 15 (11.4) | 4 (8.0) | 11 (13.4) |
| Prior local therapy for HCC | 81 (61.4) | 34 (68.0) | 47 (57.3) |
| ADA, median (IQR), ng/mL | |||
| At baseline | 0 | 0 | 0 |
| At C2D1 | 45.95 (0-257.9) | 77.45 (0-356.0) | 33.55 (0-193.1) |
| Antidrug antibody levels at C2D1 | |||
| Negative or low (<1000 ng/mL) | 109 (82.6) | 41 (82.0) | 68 (82.9) |
| High (≥1000 ng/mL) | 23 (17.4) | 9 (18.0) | 14 (17.1) |
Abbreviations: ADA, antidrug antibody; CTD1, cycle 2 day 1 of treatment; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma.